9-amino-5-ethyl-5H-phenanthridin-6-one | 711010-26-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 9-amino-5-ethyl-5H-phenanthridin-6-one
• 英文别名: 9-amino-5-ethylphenanthridin-6-one
• CAS: 711010-26-3
• 化学式: C₁₅H₁₄N₂O
• 分子量: 238.289
• InChiKey: FLXMSMBWHMPFLM-UHFFFAOYSA-N

物化性质

• 沸点：
  486.4±37.0 °C(Predicted)
• 密度：
  1.231±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  46.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N,N-二甲基甘氨酸 、 9-amino-5-ethyl-5H-phenanthridin-6-one 在 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 2-dimethylamino-N-(5-ethyl-6-oxo-5,6-dihydro-phenanthridin-9-yl)-acetamide
  参考文献：
  名称：

  Structure–activity relationships in a series of NPY Y5 antagonists: 3-amido-9-ethylcarbazoles, core-modified analogues and amide isosteres

  摘要：

  Beginning with carbazole la, the amide and alkyl substituents were optimized to maintain potency while adding solubilizing groups. Efforts to replace the 3-amino-9-ethylcarbazole core, a known carcinogen, used the SAR generated in the carbazole series for guidance and led to the synthesis of a number of core-modified analogues. In addition, an isosteric series, in which the amide was replaced with an imidazole, was prepared. Two potent new series lacking the putative toxicophore were identified from these endeavors. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00329-9
• 作为产物：
  描述：

  2-碘-4-硝基甲苯 在 palladium 10% on activated carbon 、 palladium diacetate 、 N,N-二甲基甲酰胺 chromium(VI) oxide 、 4-二甲氨基吡啶 、 草酰氯 、 硫酸 、 氢气 、 乙酸酐 、 三乙胺 、 三苯基膦 、 silver carbonate 、 potassium iodide 作用下， 以 乙醇 、 二氯甲烷 、 水 、 溶剂黄146 、 乙腈 为溶剂， 90.0 ℃ 、344.75 kPa 条件下， 反应 39.17h， 生成 9-amino-5-ethyl-5H-phenanthridin-6-one
  参考文献：
  名称：

  NPY-5 antagonists

  摘要：

  本发明提供了具有式（I）的NPY-5受体拮抗剂，同时还提供了用于治疗由上述NPY-5受体拮抗剂调节的疾病、症状和/或疾患的方法和药物组合物。

  公开号：

  US20040122038A1

文献信息

• Aminophenanthridinone and aminophenanthridine as NPY-5 antagonists
  申请人：Hammond Marlys

  公开号：US06958347B2

  公开（公告）日：2005-10-25

  The present invention provides NPY-5 receptor antagonists having a Formula (I) Methods and pharmaceutical compositions useful for treating diseases, conditions and/or disorders modulated by the above NPY-5 receptor antagonists are also provided.

  本发明提供了一种具有式(I)的NPY-5受体拮抗剂，同时还提供了用于治疗受上述NPY-5受体拮抗剂调节的疾病、状况和/或障碍的方法和制药组合物。
• 5-AMINOPHENANTHRIDINE DERIVATIVES AS NPY-5 ANTAGONISTS
  申请人：Pfizer Products Inc.

  公开号：EP1578728A1

  公开（公告）日：2005-09-28
• US6958347B2
  申请人：——

  公开号：US6958347B2

  公开（公告）日：2005-10-25
• [EN] 5-AMINOPHENANTHRIDINE DERIVATIVES AS NPY-5 ANTAGONISTS<br/>[FR] DERIVES DE 5-AMINOPHENANTHRIDINE SERVANT D'ANTAGONISTES DE NPY-5
  申请人：PFIZER PROD INC

  公开号：WO2004054981A1

  公开（公告）日：2004-07-01

  The present invention provides NPY-5 receptor antagonists having a Formula (I) Methods and pharmaceutical compositions useful for treating diseases, conditions and/or disorders modulated by the above NPY-5 receptor antagonists are also provided.
• Structure–activity relationships in a series of NPY Y5 antagonists: 3-amido-9-ethylcarbazoles, core-modified analogues and amide isosteres
  作者：Marlys Hammond、Richard L. Elliott、Melissa L. Gillaspy、David C. Hager、Richard F. Hank、Janet A. LaFlamme、Robert M. Oliver、Paul A. DaSilva-Jardine、Ralph W. Stevenson、Christine M. Mack、James V. Cassella

  DOI：10.1016/s0960-894x(03)00329-9

  日期：2003.6

  Beginning with carbazole la, the amide and alkyl substituents were optimized to maintain potency while adding solubilizing groups. Efforts to replace the 3-amino-9-ethylcarbazole core, a known carcinogen, used the SAR generated in the carbazole series for guidance and led to the synthesis of a number of core-modified analogues. In addition, an isosteric series, in which the amide was replaced with an imidazole, was prepared. Two potent new series lacking the putative toxicophore were identified from these endeavors. (C) 2003 Elsevier Science Ltd. All rights reserved.